Comparison of clinical and laboratory features and treatment options of 237 symptomatic and asymptomatic children infected with SARS-CoV-2 in the early phase of the COVID-19 pandemic in Turkey

Basit Öğe Kaydı
dc.authorscopusid23468003500
dc.authorscopusid6507971898
dc.authorscopusid57192868725
dc.authorscopusid57217973999
dc.authorscopusid57226538218
dc.authorscopusid57226540693
dc.contributor.authorSoysal, A.
dc.contributor.authorGönüllü, E.
dc.contributor.authorArslan, H.
dc.contributor.authorKibar, B. S.
dc.contributor.authorPop, S.
dc.contributor.authorYurttaş, G. N.
dc.contributor.authorAdıgüzel, O. G.
dc.date.accessioned2021-12-01T18:38:57Z
dc.date.available2021-12-01T18:38:57Z
dc.date.issued2021
dc.department[Belirlenecek]en_US
dc.description.abstractLittle is known about the therapeutic use of hydroxychloroquine in pediatric patients with coronavirus disease 2019 (COVID-19). Here, we retrospectively retrieved data of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) PCR-positive pediatric patients from 20 hospitals in 8 Turkish cities. We obtained epidemiological, clinical, and laboratory features of the patients, as well as the drugs used for treating COVID-19. A total of 237 nasopharyngeal swab SARS-CoV-2 PCR-positive children were included in the study from March 26, 2020 to June 20, 2020. The mean age of asymptomatic children (118 + 62 months) was higher than that of symptomatic children (89 + 69 months). Symptomatic children had significantly lower mean lymphocyte counts and higher mean CRP, D-dimer, procalcitonin, and LDH levels than asymptomatic children in the univariate analysis. Among 156 children, 78 (50%), 15, 44, and 21 were treated with a hydroxychloroquine-containing regimen, hydroxychloroquine + azithromycin + oseltamivir, hydroxychloroquine + azithromycin, and hydroxychloroquine alone, respectively. Among 156 patients who received medical treatment, 90 (58%) underwent pre- and/or post-treatment electrocardiogram (ECG). However, none of them had ECG abnormalities or required hydroxychloroquine discontinuation due to adverse drug reactions. © 2021, National Institute of Health. All rights reserved.en_US
dc.identifier.doi10.7883/yoken.JJID.2020.781
dc.identifier.endpage279en_US
dc.identifier.issn13446304
dc.identifier.issue4en_US
dc.identifier.pmid33250495en_US
dc.identifier.scopus2-s2.0-85107565471en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage273en_US
dc.identifier.urihttps://doi.org/10.7883/yoken.JJID.2020.781
dc.identifier.urihttps://hdl.handle.net/20.500.12684/9933
dc.identifier.volume74en_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherNational Institute of Healthen_US
dc.relation.ispartofJapanese Journal of Infectious Diseasesen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.titleComparison of clinical and laboratory features and treatment options of 237 symptomatic and asymptomatic children infected with SARS-CoV-2 in the early phase of the COVID-19 pandemic in Turkeyen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
9933-2.pdf
Boyut:
412.19 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu